This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Goldberg, S. M. Articles by Wolchok, J. D. Search for Related Content PubMed PubMed Citation Articles by Goldberg, S. M. Articles by Wolchok, J. D.

Comparison of Two Cancer Vaccines Targeting Tyrosinase: Plasmid DNA and Recombinant Alphavirus Replicon Particles

Authors' Affiliations: ¹ Departments of Medicine and Pediatrics and Immunology Program, Memorial Sloan-Kettering Cancer Center, New York, New York; ² Progenics Pharmaceuticals, Tarrytown, New York; and ³ AlphaVax, Inc., Research Triangle Park, North Carolina

Requests for reprints: Stacie M. Goldberg, Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021. Phone: 212-639-8145; Fax: 212-794-4352; E-mail: goldber3{at}mskcc.org.

Purpose: Immunization of mice with xenogeneic DNA encoding human tyrosinase-related proteins 1 and 2 breaks tolerance to these self-antigens and leads to tumor rejection. Viral vectors used alone or in heterologous DNA prime/viral boost combinations have shown improved responses to certain infectious diseases. The purpose of this study was to compare viral and plasmid DNA in combination vaccination strategies in the context of a tumor antigen.

Experimental Design: Using tyrosinase as a prototypical differentiation antigen, we determined the optimal regimen for immunization with plasmid DNA. Then, using propagation-incompetent alphavirus vectors (virus-like replicon particles, VRP) encoding tyrosinase, we tested different combinations of priming with DNA or VRP followed by boosting with VRP. We subsequently followed antibody production, T-cell response, and tumor rejection.

Results: T-cell responses to newly identified mouse tyrosinase epitopes were generated in mice immunized with plasmid DNA encoding human (xenogeneic) tyrosinase. In contrast, when VRP encoding either mouse or human tyrosinase were used as single agents, antibody and T-cell responses and a significant delay in tumor growth in vivo were observed. Similarly, a heterologous vaccine regimen using DNA prime and VRP boost showed a markedly stronger response than DNA vaccination alone.

Conclusions: Alphavirus replicon particle vectors encoding the melanoma antigen tyrosinase (self or xenogeneic) induce immune responses and tumor protection when administered either alone or in the heterologous DNA prime/VRP boost approaches that are superior to the use of plasmid DNA alone.

This article has been cited by other articles:

				M. de la Luz Garcia-Hernandez, A. Gray, B. Hubby, O. J. Klinger, and W. M. Kast Prostate Stem Cell Antigen Vaccination Induces a Long-term Protective Immune Response against Prostate Cancer in the Absence of Autoimmunity Cancer Res., February 1, 2008; 68(3): 861 - 869. [Abstract] [Full Text] [PDF]

				K. Ljungberg, A. C. Whitmore, M. E. Fluet, T. P. Moran, R. S. Shabman, M. L. Collier, A. A. Kraus, J. M. Thompson, D. C. Montefiori, C. Beard, et al. Increased Immunogenicity of a DNA-Launched Venezuelan Equine Encephalitis Virus-Based Replicon DNA Vaccine J. Virol., December 15, 2007; 81(24): 13412 - 13423. [Abstract] [Full Text] [PDF]

				R. J. Durso, S. Andjelic, J. P. Gardner, D. J. Margitich, G. P. Donovan, R. R. Arrigale, X. Wang, M. F. Maughan, T. L. Talarico, R. A. Olmsted, et al. A Novel Alphavirus Vaccine Encoding Prostate-Specific Membrane Antigen Elicits Potent Cellular and Humoral Immune Responses Clin. Cancer Res., July 1, 2007; 13(13): 3999 - 4008. [Abstract] [Full Text] [PDF]

				T. I. Naslund, C. Uyttenhove, E. K. L. Nordstrom, D. Colau, G. Warnier, M. Jondal, B. J. Van den Eynde, and P. Liljestrom Comparative Prime-Boost Vaccinations Using Semliki Forest Virus, Adenovirus, and ALVAC Vectors Demonstrate Differences in the Generation of a Protective Central Memory CTL Response against the P815 Tumor J. Immunol., June 1, 2007; 178(11): 6761 - 6769. [Abstract] [Full Text] [PDF]